US Patent

US10093654 — Therapeutically active compounds and their methods of use

Method of Use · Assigned to Agios Pharmaceuticals Inc · Expires 2034-08-01 · 8y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects compounds useful for treating cancer and methods of administering those compounds to a subject in need thereof.

USPTO Abstract

Provided are compounds useful for treating cancer and methods of treating cancer, comprising administering to a subject in need thereof a compound described herein.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2087 — enasidenib-mesylate
U-2087 — enasidenib-mesylate

Patent Metadata

Patent number
US10093654
Jurisdiction
US
Classification
Method of Use
Expires
2034-08-01
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Agios Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.